Enzo Biochem Inc
NYSE:ENZ
Enzo Biochem Inc
Operating Income
Enzo Biochem Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Enzo Biochem Inc
NYSE:ENZ
|
Operating Income
-$36.7m
|
CAGR 3-Years
-83%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-14%
|
|
DaVita Inc
NYSE:DVA
|
Operating Income
$1.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-1%
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Operating Income
$1.3B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
CVS Health Corp
NYSE:CVS
|
Operating Income
$13.6B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
Cigna Corp
NYSE:CI
|
Operating Income
$9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
15%
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Operating Income
$1.1B
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
2%
|
See Also
What is Enzo Biochem Inc's Operating Income?
Operating Income
-36.7m
USD
Based on the financial report for Jan 31, 2024, Enzo Biochem Inc's Operating Income amounts to -36.7m USD.
What is Enzo Biochem Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-14%
Over the last year, the Operating Income growth was -18%. The average annual Operating Income growth rates for Enzo Biochem Inc have been -83% over the past three years , -15% over the past five years , and -14% over the past ten years .